Keele Research Repository

Article

Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.

Coles, C, Griffin, C, Kirby, A, Agrawal, R, Alhasso, A, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, H, Donovan, E, Emson, M, Harnett, A, Haviland, J, Hopwood, P, Jefford, M, Kaggwa, R, Sawyer, E, Sybdikus, I, Tsang, Y, Wheatley, D, Wilcox, M, Yarnold, J and Bliss, J (2017) Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology, 123 (S1). S162 -S163.

Agrawal, R, Dale, TP, Al-Zubaidi, MA, Benny Malgulwar, P, Forsyth, NR and Kulshreshtha, R (2016) Pluripotent and Multipotent Stem Cells Display Distinct Hypoxic miRNA Expression Profiles. PLoS One, 11 (10). e0164976 -?.

Earl, HM, Hiller, H, Vallier, A-L, Bowden, SJ, Jordan, SD, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, DA, Agrawal, R, Fernando, I, Brunt, AM, O'Reilly, SM, Crawford, SM, Rea, DW, Simmonds, P, Mansi, JL, Stanley, A, McAdam, K, Foster, L, Leonard, RCF, Twelves, CJ, Cameron, D, Bartlett, JMS, Pharoah, P, Provenzano, E, Caldas, C and Poole, CJ (2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 107 (8). pp. 1257-1267.